Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs-Reference-Cited by-同舟云学术

Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

Published:2020-08-01 Issue:2 Volume:20 Page:45-55
ISSN:1335-8421
Container-title:Acta Medica Martiniana
language:en
Short-container-title:

Author:

Prso K¹,Zidekova N¹,Dohal M¹,Porvaznik I²³,Prso M⁴,Kertys M¹,Mokry J¹

Affiliation:

1. Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin , Comenius University in Bratislava , Martin , Slovakia

2. Department of Clinical Microbiology , National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery , Vyšné Hágy , Slovakia

3. Faculty of Health , Catholic University , Ružomberok , Slovakia

4. Clinic of Children and Adolescents , Jessenius Faculty of Medicine in Martin , Comenius University in Bratislava, and Martin University Hospital , Martin , Slovak Republic

Abstract

Abstract Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible Mycobacterium tuberculosis strains. Therapeutic drug monitoring presents a useful technique for the determination of plasma drug concentration to adjust appropriate dose regimes. In tuberculosis treatment, therapeutic drug monitoring is aiding clinicians in selecting an optimal therapeutic level, which is essential for the personalisation of therapy. This review is aimed at clarifying the use of therapeutic drug monitoring of the first-line antituberculosis drugs in routine clinical practice.

Publisher

Walter de Gruyter GmbH

Subject

General Biochemistry, Genetics and Molecular Biology,General Nursing

Link

https://www.sciendo.com/pdf/10.2478/acm-2020-0006

Reference55 articles.

1. 1. Gordon SV, Parish T. Microbe Profile: Mycobacterium tuberculosis: Humanity’s deadly microbial foe. Microbiology. 2018;164(4):437-439.

2. 2. World Health Organisation. Global Tuberculosis Report 2019. Geneva: WHO; 2020.

3. 3. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863.

4. 4. Porvaznik I, Mokry J, Solovic I. Drug resistance to anti-tuberculotics in children – three years status in Slovakia. Acta Medica Martiniana. 2013;13(3):18-22.

5. 5. Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf. 2007;16(10):1104-1110.